Inovio Pharma (INO) Stock Price, Quote & News

Company Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 440 4200

Website: www.inovio.com

Address:

660 West Germantown Pike, Suite 110, Plymouth Meeting, United States

SuperGreenToday Apr. 29 at 2:31 AM

$INO Share Price: $1.15 Contract Selected: May 22, 2026 $0.5 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.29 – $0.35 Potential Upside: 58% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Nordica Apr. 28 at 7:56 PM

$INO If the schedule holds, data unblinding of the China phase 3 trial of VGX-3100 for Cervical Dysplasia will occur THIS quarter. Also the process is..

1 · Reply

Goldmember6 Apr. 28 at 7:51 PM

$INO seems ole harm lose his back porch plowed

0 · Reply

Iluvfor30s Apr. 28 at 7:14 PM

$INO Haven't really paid much attention to details...but I just found out that VGXI is basically done due to lack of funding. Was this reported on end of last year?

1 · Reply

tau72 Apr. 28 at 2:21 PM

$INO Surprised that there was no reply/response from VGXI after INO filed the Objection/Opposition against the Defendant (VGXI) motion to withdraw on 4/15/26 as they usually responded within or day or 2 in the past... Anyone wants to speculate? 502 E 4/15/2026 Objection/Opposition BY INOVIO PHARMAECUTICALS INC TO DEFENDANTS' MOTION TO WITHDRAW WITH MEMORANDUM OF LAW WITH SERVICE ON 04/15/2026

1 · Reply

DragonAlgo Apr. 28 at 1:48 PM

🐉 $INO CALL — DragonAlgo® Signal Contract: INO CALL Expiry: 2026-05-01 | Strike: $1.00 | Type: CALL Option Plan (premium): Entry: $0.23 Stop: $0.17 TP1: $0.30 TP2: $0.39 TP3: $0.55 🔗 https://dragonalgo.com

0 · Reply

GorillaofWallStreet Apr. 28 at 12:33 PM

$INO An unnamed Inovian when he was a child.

0 · Reply

updownsides Apr. 28 at 4:48 AM

$INO Bottom line. If you try to compete with BP and mRNA, you will get decimated. They could literally buy Inovio for next to nothing and shut it down for good. Without electroporation, DNA therapy is useless. It's too obvious Cellectra will cause a CRL and practically kill DNA for many more years to come.

0 · Reply

updownsides Apr. 28 at 3:52 AM

$INO

0 · Reply

updownsides Apr. 28 at 2:44 AM

$INO

1 · Reply

INOVIO Announces Pricing of $17.5 Million Public Offering

Apr 1, 2026, 8:05 PM EDT - 27 days ago

INOVIO Announces Proposed Public Offering

Apr 1, 2026, 10:29 AM EDT - 27 days ago

INOVIO to Participate in Upcoming Scientific Conference

Mar 13, 2026, 10:32 AM EDT - 6 weeks ago

Inovio Stock Up On Earnings, Pipeline Progress

Mar 12, 2026, 4:30 PM EDT - 6 weeks ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:05 PM EDT - 6 weeks ago

INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 10, 2026, 1:40 PM EDT - 7 weeks ago

Inovio Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 8:05 AM EDT - 7 weeks ago

INOVIO to Participate in Upcoming Scientific Conferences

Mar 5, 2026, 4:05 PM EST - 7 weeks ago

INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Mar 4, 2026, 8:52 AM EST - 7 weeks ago

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

Mar 4, 2026, 8:05 AM EST - 7 weeks ago

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

Feb 25, 2026, 12:40 PM EST - 2 months ago

Inovio Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 12, 2026, 8:05 AM EST - 2 months ago

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Dec 29, 2025, 8:05 AM EST - 4 months ago

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Dec 19, 2025, 4:05 PM EST - 4 months ago

INOVIO Reports Inducement Grant Under Inducement Plan

Dec 2, 2025, 8:30 AM EST - 5 months ago

Inovio Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 8:05 AM EST - 5 months ago

INOVIO to Participate in December Investor Conferences

Nov 11, 2025, 8:40 AM EST - 6 months ago

INOVIO Announces Pricing of $25 Million Public Offering

Nov 10, 2025, 4:30 PM EST - 6 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:05 PM EST - 6 months ago

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 3, 2025, 8:05 AM EST - 6 months ago

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

Oct 27, 2025, 8:05 AM EDT - 6 months ago

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

Oct 23, 2025, 4:05 PM EDT - 6 months ago

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Oct 21, 2025, 8:05 AM EDT - 6 months ago

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Inovio Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:05 AM EDT - 8 months ago

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

Aug 25, 2025, 8:05 AM EDT - 8 months ago

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:05 PM EDT - 9 months ago

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 11, 2025, 8:05 AM EDT - 9 months ago

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Aug 4, 2025, 4:05 PM EDT - 9 months ago

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 7, 2025, 4:05 PM EDT - 10 months ago

INOVIO to Present at Upcoming Scientific Conference

Jul 1, 2025, 7:00 AM EDT - 10 months ago

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

May 13, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 11:30 AM EDT - 1 year ago

Inovio Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific and Investor Conferences

Apr 29, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 9, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific Conferences

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 4:05 PM EDT - 1 year ago

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 13, 2025, 6:15 PM EDT - 1 year ago

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Mar 12, 2025, 12:55 PM EDT - 1 year ago

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Feb 12, 2025, 3:20 PM EST - 1 year ago

Inovio Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 8:00 AM EST - 1 year ago

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Feb 10, 2025, 8:05 AM EST - 1 year ago

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Jan 29, 2025, 4:14 PM EST - 1 year ago

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 8:04 AM EST - 1 year ago

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Nov 14, 2024, 4:30 PM EST - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q3 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q2 2024

May 20, 2024, 12:30 PM EDT - 2 years ago

Inovio Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 10:00 AM EDT - 2 years ago

Inovio Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference

May 14, 2024, 11:30 AM EDT - 2 years ago

Inovio Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 4:30 PM EDT - 2 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2024

Mar 6, 2024, 4:30 PM EST - 2 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2023

Feb 14, 2024, 12:40 PM EST - 2 years ago

Inovio Pharmaceuticals Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Nov 9, 2023, 4:30 PM EST - 2 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q3 2023

Aug 9, 2023, 4:30 PM EDT - 2 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q2 2023

May 10, 2023, 4:30 PM EDT - 3 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2023

Mar 1, 2023, 4:30 PM EST - 3 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2022

Nov 8, 2022, 8:00 AM EST - 3 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q3 2022

Aug 9, 2022, 4:30 PM EDT - 4 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q2 2022

May 10, 2022, 8:43 AM EDT - 4 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2022

Mar 1, 2022, 6:27 AM EST - 4 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2021

Nov 8, 2021, 7:00 PM EST - 4 years ago

Inovio Pharmaceuticals Earnings Call Transcript: Q3 2021

SuperGreenToday Apr. 29 at 2:31 AM

0 · Reply

Nordica Apr. 28 at 7:56 PM

$INO If the schedule holds, data unblinding of the China phase 3 trial of VGX-3100 for Cervical Dysplasia will occur THIS quarter. Also the process is..

1 · Reply

Goldmember6 Apr. 28 at 7:51 PM

$INO seems ole harm lose his back porch plowed

0 · Reply

Iluvfor30s Apr. 28 at 7:14 PM

$INO Haven't really paid much attention to details...but I just found out that VGXI is basically done due to lack of funding. Was this reported on end of last year?

1 · Reply

tau72 Apr. 28 at 2:21 PM

1 · Reply

DragonAlgo Apr. 28 at 1:48 PM

0 · Reply

GorillaofWallStreet Apr. 28 at 12:33 PM

$INO An unnamed Inovian when he was a child.

0 · Reply

updownsides Apr. 28 at 4:48 AM

0 · Reply

updownsides Apr. 28 at 3:52 AM

$INO

0 · Reply

updownsides Apr. 28 at 2:44 AM

$INO

1 · Reply

BentleyT99 Apr. 27 at 6:40 PM

$INO We Got This!!!!!!

0 · Reply

Inoboatguy Apr. 27 at 2:59 PM

$INO

0 · Reply

rioe Apr. 27 at 2:25 PM

$INO let’s go!! 🚀🚀

1 · Reply

INOVIO Apr. 27 at 2:22 PM

$INO Moontime has started! Buckle up!

0 · Reply

blueboy67 Apr. 27 at 2:18 PM

$INO hmmm . nice volume..news maybe🤔

0 · Reply

joeddie23 Apr. 27 at 2:17 PM

$INO bought more. We are going to know something soon on that meeting .

1 · Reply

GorillaofWallStreet Apr. 27 at 12:40 PM

$INO Keep them jokes comin Bentley. We need more humor in this world. BentleyT99 Ben Roth @BentleyT99 $INO Big Royalties And Milestone Payments Should Begin Summer Of 2026 Bullish

0 · Reply

Tracker7 Apr. 27 at 2:37 AM

$INO Happy DNA Day!

0 · Reply

BentleyT99 Apr. 26 at 7:56 PM

$INO Big Royalties And Milestone Payments Should Begin Summer Of 2026

1 · Reply

RajCx Apr. 25 at 1:35 AM

$INO As I suspected, short numbers reported today after dilution. Shorts have ramped up 🙄

1 · Reply

Inoboatguy Apr. 24 at 9:16 PM

$REGN when buy $INO ??

2 · Reply

Goldmember6 Apr. 24 at 8:07 PM

$INO bentley aka barry from newyork has claimed china=russia=brazille=cuba=north korea=and pluto for in 6 months for the last 7 years. and all it does is tank lower.. what a dork

1 · Reply

Market Cap	79.85M
Revenue (ttm)	70,000.00
Net Income (ttm)	-84.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-121,357.14%
Debt to Equity Ratio	0.00

Volume	1,076,300
Avg Vol	1,746,278
Day's Range	N/A - N/A
Shares Out	69.44M
Stochastic %K	30%
Beta	1.70
Analysts	Sell
Price Target	$5.96